FIG 2.

(A) Swimmer plot demonstrating different treatment modalities (surgery; chemotherapy, radiotherapy) and treatment with larotrectinib, along with best tumor response achieved by each treatment approach. (B) Best response to the NTRK inhibitor (larotrectinib) for each individual patient that had their tumor images centrally and independently reviewed. The response is associated with tumor type, NTRK fusion subtype, patients' clinical status at the last follow-up, and the observation time since the start of therapy with larotrectinib in months. CR, complete response; IFS, infantile fibrosarcoma; NBL, neuroblastoma; NTRK, neurotrophic tropomyosin receptor kinase; PD, progressive disease; PR, partial response; SD, stable disease; STS, other soft tissue sarcomas.